SIGA Technologies (NASDAQ: SIGA) and VBI Vaccines (NASDAQ:VBIV) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.
Institutional and Insider Ownership
31.5% of VBI Vaccines shares are held by institutional investors. 54.5% of VBI Vaccines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares SIGA Technologies and VBI Vaccines’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares SIGA Technologies and VBI Vaccines’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|SIGA Technologies||$21.28 million||7.69||-$18.34 million||N/A||N/A|
|VBI Vaccines||$888,999.00||166.53||-$32.88 million||N/A||N/A|
SIGA Technologies has higher revenue and earnings than VBI Vaccines.
This is a summary of current ratings and price targets for SIGA Technologies and VBI Vaccines, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
VBI Vaccines has a consensus target price of $6.00, suggesting a potential upside of 63.04%. Given VBI Vaccines’ higher probable upside, analysts clearly believe VBI Vaccines is more favorable than SIGA Technologies.
VBI Vaccines beats SIGA Technologies on 7 of the 9 factors compared between the two stocks.
SIGA Technologies Company Profile
SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.
VBI Vaccines Company Profile
VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.
Receive News & Ratings for SIGA Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.